• Je něco špatně v tomto záznamu ?

Safety of the Geneva Cocktail, a Cytochrome P450 and P-Glycoprotein Phenotyping Cocktail, in Healthy Volunteers from Three Different Geographic Origins

V. Rollason, M. Mouterde, Y. Daali, M. Čížková, E. Priehodová, I. Kulichová, H. Posová, J. Petanová, A. Mulugeta, E. Makonnen, A. Al-Habsi, R. Davidson, KK. Al-Balushi, K. Al-Thihli, M. Cerná, S. Al-Yahyaee, V. Černý, G. Yimer, ES. Poloni, J. Desmeules

. 2020 ; 43 (11) : 1181-1189. [pub] -

Jazyk angličtina Země Nový Zéland

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026444
E-zdroje Online Plný text

NLK ProQuest Central od 2008-06-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2008-06-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2008-06-01 do Před 1 rokem

Odkazy

PubMed 32851583
DOI 10.1007/s40264-020-00983-8
Knihovny.cz E-zdroje

INTRODUCTION AND OBJECTIVE: Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations.MATERIALS AND METHODS: The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes' concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. RESULTS: A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. CONCLUSIONS: In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026444
003      
CZ-PrNML
005      
20230704112750.0
007      
ta
008      
211013s2020 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40264-020-00983-8 $2 doi
035    __
$a (PubMed)32851583
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Rollason, Victoria $u Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland. Victoria.Rollason@hcuge.ch
245    10
$a Safety of the Geneva Cocktail, a Cytochrome P450 and P-Glycoprotein Phenotyping Cocktail, in Healthy Volunteers from Three Different Geographic Origins / $c V. Rollason, M. Mouterde, Y. Daali, M. Čížková, E. Priehodová, I. Kulichová, H. Posová, J. Petanová, A. Mulugeta, E. Makonnen, A. Al-Habsi, R. Davidson, KK. Al-Balushi, K. Al-Thihli, M. Cerná, S. Al-Yahyaee, V. Černý, G. Yimer, ES. Poloni, J. Desmeules
520    9_
$a INTRODUCTION AND OBJECTIVE: Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations.MATERIALS AND METHODS: The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes' concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. RESULTS: A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. CONCLUSIONS: In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.
650    _2
$a P-glykoprotein $x genetika $x metabolismus $7 D020168
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a inhibitory cytochromu P450 $7 D065607
650    _2
$a systém (enzymů) cytochromů P-450 $x genetika $x metabolismus $7 D003577
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a genotyp $7 D005838
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a léčivé přípravky $x metabolismus $7 D004364
650    _2
$a substrátová specifita $7 D013379
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
651    _2
$a Etiopie $7 D005002
651    _2
$a Omán $7 D009850
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mouterde, Médéric $u Department of Genetics and Evolution (GENEV), Anthropology Unit, University of Geneva, 30, Quai Ernest-Ansermet, 1205 Geneva, Switzerland. Mederic.Mouterde@unige.ch
700    1_
$a Daali, Youssef $u Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland
700    1_
$a Čížková, Martina $u Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Priehodová, Edita $u Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Kulichová, Iva $u Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Posová, Helena $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Petanová, Jitka $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mulugeta, Anwar $u Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
700    1_
$a Makonnen, Eyasu $u Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia $u Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
700    1_
$a Al-Habsi, Abir $u Oman Specialty Board, Muscat, Sultanate of Oman
700    1_
$a Davidson, Robin $u Department of Family Medicine, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
700    1_
$a Al-Balushi, Khalid K $u Department of Pharmacology and Clinical Pharmacy, Sultan Qaboos University, Muscat, Sultanate of Oman
700    1_
$a Al-Thihli, Khalid $u Department of Genetics, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
700    1_
$a Cerná, Marie $u Department of Medical Genetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Al-Yahyaee, Said $u Department of Genetics, College of Medicine and Health Sciences, Muscat, Sultanate of Oman
700    1_
$a Černý, Viktor, $u Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic $d 1964- $7 xx0031073
700    1_
$a Yimer, Getnet $u Global One Health Initiative, Office of International Affairs, The Ohio State University, Columbus, OH, USA
700    1_
$a Poloni, Estella S $u Department of Genetics and Evolution (GENEV), Anthropology Unit, University of Geneva, 30, Quai Ernest-Ansermet, 1205 Geneva, Switzerland $u Institute of Genetics and Genomics of Geneva (iGE3), Geneva, Switzerland
700    1_
$a Desmeules, Jules $u Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland
773    0_
$w MED00001449 $t Drug safety $x 1179-1942 $g Roč. 43, č. 11 (2020), s. 1181-1189
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32851583 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20230704112747 $b ABA008
999    __
$a ok $b bmc $g 1715228 $s 1146951
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 43 $c 11 $d 1181-1189 $e - $i 1179-1942 $m Drug safety $n Drug Saf $x MED00001449
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace